Nurix therapeutics to present at the oppenheimer 33rd annual healthcare conference

San francisco, march 06, 2023 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that arthur t. sands, m.d., ph.d., nurix's president and chief executive officer, will provide a corporate overview at the oppenheimer 33rd annual healthcare conference (virtual) on tuesday, march 14 at 10:40 a.m. et.
NRIX Ratings Summary
NRIX Quant Ranking